How Patient Advocates Can Help the Newly Diagnosed

EP: 1.Differences Between SERDs and Other Therapies

EP: 2.Efficacy of Oral SERDs in the EMERALD Trial

EP: 3.Safety Concerns Associated With Oral SERDs

EP: 4.Benefits of Using Oral SERDs

EP: 5.Progression-Free Survival of Oral SERDs in Clinical Practice

EP: 6.Role of Oral SERDs in Treatment of ER+/HER2- in Metastatic Breast Cancer

EP: 7.ESR1 Mutation Confirmation With Oral SERDs

EP: 8.Coverage Considerations for Oral SERDs

EP: 9.Clinical Impact of Oral SERDs

EP: 10.Treatment Failure and Resistance Before Oral SERDs

EP: 11.Cardiovascular Risk and Menopausal Symptoms Associated With Oral SERDs

EP: 12.Monitoring and Managing Adverse Effects With Oral SERDs

EP: 13.Payer Perspectives on SERDs

EP: 14.Ensuring Access to Oral SERDs

Now Viewing

EP: 15.How Patient Advocates Can Help the Newly Diagnosed

EP: 16.Empowering Patients With Metastatic Breast Cancer

EP: 17.Helping Patients With Metastatic Breast Cancer Enroll in Clinical Trials

EP: 18.Guiding Patients Through Complex Treatment Decisions

EP: 19.Patient Advocate's Role in Shared Decision Making

EP: 20.Helping Patients Overcome Health Disparities as a Patient Advocate

Sonya Negley, IOM, CSMA: I think the most important thing for patient advocates and patient advocacy organizations is to make sure that we have the correct, most recent data. The information about new treatment options coming to market can be overwhelming, and while it can be protracted, it also comes to market quickly. So, it’s important we as patient advocacy organizations have a good idea of what that means and what that means for the patients. The best thing individual patient advocates can do is get involved, and have a voice in what is going on with metastatic breast cancer.

For a lot of people who have cancer in general, most of their treatment options are pretty straightforward, and for the most part, their cancer can be contained or cured. But in metastatic breast cancer, that’s not where we are yet. We are at a point where there are a lot of discoveries happening, a lot of personalized medicine; however, it’s not a disease that is not terminal. It’s not chronic, it’s not curable. So, the best thing patient advocates can do is share their voice, share the importance of research. It is paramount that we fund research to make sure we can get to those good treatment options or treatment bridges, and hopefully soon, have a discovery that will render this disease survivable. Sharing stories of what they’ve gone through [is important]. Not necessarily saying to another patient that their journey equals the newly diagnosed journey, but rather, sharing their experiences so others can understand that you can have a good quality of life, and there are lessons [to be] learned from other patient advocates.

Transcript edited for clarity